Which Blood Values Should Be Monitored During GLP-1 Treatment?

GLP-1 treatment is a medical approach used for blood sugar control, appetite regulation, weight management and reduction of metabolic risks. The World Health Organization defines GLP-1 treatments as an option that should be considered in the long-term management of obesity together with healthy nutrition, physical activity and professional healthcare support.

During this treatment process, not only weight change but also blood sugar, kidney function, liver enzymes, lipid profile and certain metabolic markers should be monitored regularly. Because GLP-1 medicines may slow digestion, reduce appetite, affect blood sugar balance and cause gastrointestinal side effects in some people.

Fasting Blood Glucose And HbA1c

One of the main follow-up areas during GLP-1 treatment is fasting blood glucose and HbA1c. Fasting blood glucose shows the glucose level at the time of measurement, while HbA1c provides information about the average blood sugar level over approximately the last three months. Therefore, regular monitoring is important, especially in people with type 2 diabetes, prediabetes or insulin resistance.

The World Health Organization states that type 2 diabetes accounts for the vast majority of all diabetes cases and that impaired fasting glucose and impaired glucose tolerance are intermediate conditions that increase the risk of progression to diabetes. Therefore, in people receiving GLP-1 treatment, blood sugar values show not only the response to treatment but also the course of diabetes risk.

The main measurements that may be evaluated during follow-up include:

• Fasting Blood Glucose: This is the glucose level measured in the morning after fasting and is one of the basic indicators of glucose metabolism.
• HbA1c: This provides an idea about the average blood sugar level over the last 2-3 months and is an important parameter in diabetes follow-up.
• Postprandial Blood Glucose: This shows the glucose response after meals and may be more explanatory than fasting blood glucose in some patients.

Insulin And HOMA-IR

Since GLP-1 treatment may be considered in people with obesity, insulin resistance and risk of type 2 diabetes, insulin level and HOMA-IR evaluation may also be included in the follow-up plan. HOMA-IR is an indicator calculated together with fasting insulin and fasting blood glucose, providing an idea about insulin resistance.

In people with insulin resistance, the body may have to secrete more insulin to balance blood sugar. Over time, this may make weight control more difficult, increase fat accumulation around the abdomen and raise the risk of type 2 diabetes. Therefore, during the GLP-1 process, it is valuable to look not only at weight loss but also at changes in insulin response.

The main measurements that may be evaluated during follow-up include:

• Fasting Insulin: This shows how much insulin the body secretes during fasting.
• HOMA-IR: This is a calculation used to evaluate the risk of insulin resistance.
• Interpretation Together With Fasting Glucose: Insulin should not be evaluated alone, but together with blood sugar.

Kidney Function Tests

Monitoring kidney function during GLP-1 treatment is important. Kidney function may be affected especially in people who experience nausea, vomiting, diarrhea or fluid loss. In the product information of some GLP-1 medicines, it is stated that kidney function should be monitored in patients who experience side effects that may lead to dehydration.

Kidney follow-up should be planned more carefully, especially in people with additional risk factors such as diabetes, hypertension, chronic kidney disease history or advanced age. Because screening and monitoring kidney disease in diabetes management is an important step in preventing complications.

The main measurements that may be evaluated during follow-up include:

• Creatinine: This is one of the main blood tests used to evaluate kidney function.
• eGFR: This provides information about the filtering capacity of the kidneys.
• Urea: This is evaluated in relation to kidney function, fluid balance and protein metabolism.
• Urine Albumin/Creatinine Ratio: This may be guiding in terms of kidney damage, especially in people at risk of diabetes.

Liver Enzymes

Fatty liver may be seen more frequently in people with obesity, insulin resistance and risk of type 2 diabetes. Therefore, monitoring liver enzymes such as ALT, AST and GGT during GLP-1 treatment is important for understanding the metabolic picture. GLP-1 treatments may be associated with positive effects on liver health in some people together with weight loss and metabolic improvement; however, follow-up should be individualized.

Liver enzymes alone do not establish a diagnosis. However, elevated values may require medical evaluation in terms of fatty liver, biliary problems, medication effects or other metabolic causes. Therefore, seeing baseline values before treatment and monitoring them comparatively during the process provides a healthier approach.

The main measurements that may be evaluated during follow-up include:

• ALT: This may be evaluated in terms of liver cell injury or fatty liver.
• AST: This is an enzyme that may be associated with different tissues, including the liver and muscle tissue.
• GGT: This may be used in evaluations related to the bile ducts and liver metabolism.
• Total Bilirubin: This may provide additional information about the liver and biliary system.

Lipid Profile

Since GLP-1 treatment is usually planned with the goal of weight management and reduction of metabolic risks, cholesterol and triglyceride levels should also be monitored. In people with obesity, insulin resistance and risk of type 2 diabetes, LDL cholesterol, HDL cholesterol and triglyceride levels are important indicators of cardiometabolic risk.

The World Health Organization states that in people with diabetes, blood pressure and cholesterol management, in addition to blood sugar-lowering treatments, is important in reducing the risk of complications. Therefore, in people receiving GLP-1 treatment, lipid profile should be evaluated not only as part of the weight loss process but also as part of cardiovascular risk management.

The main measurements that may be evaluated during follow-up include:

• Total Cholesterol: This provides information about the overall cholesterol burden.
• LDL Cholesterol: This is closely monitored in terms of cardiovascular risk.
• HDL Cholesterol: This is known as protective cholesterol and is important for metabolic health.
• Triglycerides: These may be associated with insulin resistance, fatty liver and cardiometabolic risk.

Values Related To The Pancreas And Gallbladder

Gastrointestinal side effects may be common with GLP-1 treatments. The World Health Organization states that nausea, vomiting, constipation and diarrhea are among common side effects, while gallbladder diseases, acute pancreatitis, intestinal obstruction and gastroparesis are among more serious conditions that should be monitored.

Therefore, if symptoms such as severe and persistent abdominal pain, pain radiating to the back, recurrent vomiting, jaundice, dark urine or right upper abdominal pain occur, medical evaluation should not be delayed. Routine amylase or lipase monitoring may not be necessary at the same frequency for everyone; however, these values become important if there are clinical symptoms.

The main measurements that may be evaluated during follow-up include:

• Lipase: This is an important enzyme that may be evaluated in complaints related to the pancreas.
• Amylase: This may be requested in conditions related to the pancreas and digestive system.
• Bilirubin: This may be evaluated in terms of bile ducts and liver function.
• ALP And GGT: These may help in the evaluation of bile flow and the liver-biliary system.

Electrolytes And Fluid Balance

During GLP-1 treatment, decreased appetite, eating less, nausea, vomiting or diarrhea may affect fluid and electrolyte balance. Therefore, sodium, potassium and other electrolytes may need to be checked, especially in people who have significant gastrointestinal complaints, cannot take enough fluids or have additional illnesses.

Electrolyte imbalance may cause symptoms such as weakness, palpitations, dizziness, muscle cramps and low blood pressure. These findings should not be seen as a natural part of the weight loss process, especially if they occur together with rapid weight loss or intense vomiting and diarrhea.

The main measurements that may be evaluated during follow-up include:

• Sodium: This is related to fluid balance and blood pressure.
• Potassium: This is important for heart rhythm and muscle functions.
• Chloride: This helps in the evaluation of fluid-electrolyte balance.
• Magnesium: This may be evaluated in terms of muscle function, energy metabolism and rhythm balance.

Vitamin And Mineral Values

During GLP-1 treatment, decreased appetite and smaller portions may make adequate protein, vitamin and mineral intake difficult in some people. Vitamin and mineral follow-up becomes more important especially in long-term treatments, in people who lose weight rapidly or in patients whose nutrition is significantly restricted.

This follow-up does not mean that the medication directly causes a deficiency. However, some values may need to be monitored due to reduced food intake, one-sided nutrition, accompanying gastrointestinal complaints or previously existing deficiencies. Evaluation should be based on the person’s eating pattern, symptoms and additional diseases.

The main measurements that may be evaluated during follow-up include:

• Vitamin B12: This is important for energy metabolism, the nervous system and blood cells.
• Vitamin D: This is associated with bone health, immunity and metabolic health.
• Ferritin And Iron: These may be evaluated in terms of iron stores and anemia risk.
• Folate: This is important for blood cells and cellular metabolism.

Complete Blood Count

Complete blood count is one of the basic tests that may be used to evaluate general health status during GLP-1 treatment. Hemoglobin, hematocrit, white blood cells and platelets may provide information about anemia, infection, inflammation or the general body response.

Complete blood count becomes more meaningful especially in the presence of rapid weight loss, significant fatigue, dizziness, loss of appetite, inadequate nutrition or additional chronic disease. For treatment to progress safely, not a single value but the person’s overall clinical picture and comparison with previous results should be considered.

The main measurements that may be evaluated during follow-up include:

• Hemoglobin: This is one of the basic indicators for anemia.
• Hematocrit: This may provide an idea about blood cell concentration and fluid balance.
• Leukocytes: These may be used in the evaluation of infection or inflammation.
• Platelets: These are evaluated in relation to the bleeding-clotting balance.

Thyroid Values

Before GLP-1 treatment, evaluating personal and family medical history is important. In the product information of some GLP-1 medicines, contraindication warnings are included for people with a history of medullary thyroid cancer or multiple endocrine neoplasia type 2. Therefore, the treatment decision must be made by a physician, taking personal risks into account.

Thyroid function tests are not considered a standard mandatory follow-up for GLP-1 treatment, but they may be evaluated in terms of the person’s symptoms, goiter history, previous thyroid disease or hormonal causes that may affect weight change. Especially if symptoms such as weight gain, fatigue, palpitations, hair loss or menstrual irregularity are present, the thyroid panel becomes more meaningful.

The main measurements that may be evaluated during follow-up include:

• TSH: This is one of the basic screening tests for thyroid function.
• Free T4: This helps evaluate thyroid hormone levels.
• Free T3: This may provide additional information in some clinical situations.
• Thyroid Antibodies: These may be requested when autoimmune thyroid disease is suspected.

How Should Follow-Up Frequency Be Planned?

The frequency of follow-up in GLP-1 treatment varies according to the person’s baseline weight, diabetes or prediabetes status, kidney-liver functions, other medications used and side effect status. Therefore, a single standard follow-up interval may not be correct for everyone.

In the general approach, baseline blood values should be seen before treatment, side effects should be evaluated during dose escalation periods and metabolic response should be monitored at certain intervals. In people with diabetes, hypertension, kidney disease, fatty liver or cardiovascular risk, follow-up may be planned more closely.

Key points in the follow-up plan include:

• Pre-Treatment Evaluation: Blood sugar, HbA1c, kidney, liver, lipid and general metabolic values are checked.
• Dose Escalation Period: Monitoring is performed for nausea, vomiting, diarrhea, fluid loss and low blood sugar.
• Regular Control: Weight loss, waist circumference, blood pressure, blood sugar and laboratory values are evaluated together.
• Individualized Planning: If diabetes, insulin use, kidney disease or gallbladder history is present, follow-up is performed more carefully.

Happ Health And Online Endocrinology Doctor Support

GLP-1 treatment is a process that should be evaluated holistically not only for weight loss, but also in terms of blood sugar balance, insulin resistance, obesity, type 2 diabetes risk and metabolic health. Therefore, it is important that blood values are interpreted under physician supervision before and during treatment.

Happ Health is a digital health platform that facilitates access to specialist physician support in endocrinology through its online health application. For your questions about GLP-1 treatment, insulin resistance, obesity or type 2 diabetes risk, you can plan an online endocrinology doctor consultation and receive professional support in evaluating your blood values according to your personal health status.

References

• World Health Organization, Global Guideline On The Use Of GLP-1 Medicines In Treating Obesity
  https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
• World Health Organization, Obesity And GLP-1 Therapies Questions And Answers
  https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies
• World Health Organization, Diabetes Fact Sheet
  https://www.who.int/news-room/fact-sheets/detail/diabetes
• American Diabetes Association, Standards Of Care In Diabetes 2026
  https://professional.diabetes.org/standards-of-care
• FDA, GLP-1 Medicine Label Information
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf